The re-emergence from the COVID-19 epidemic of Beijing Xinfadi Market

To provide references for global pandemic prevention and control, this study aimed to analyze the epidemiological characteristics and clinical manifestations of 103 new confirmed cases between June 12 and June 15, 2020, in Beijing. All confirmed cases in this study were tested with a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction and extracting data from the Beijing Municipal Health Commission (June 11 to July 6, 2020). We selected the 103 typical confirmed cases (excluding imported cases) between June 12 and June 15 for statistical analysis and explored differences among different clinical cases. A cluster of COVID-19 was reported in Beijing between June 12 and June 15, 2020, involving 103 confirmed cases. Patients aged 21 to 65 years old and the mean age was 42.38 ± 11.507, the male-to-female sex ratio was 1.40:1. All confirmed cases had a direct or indirect exposure history in the Beijing Xinfadi Market (BXM), and the clinical manifestations of 97% confirmed cases was diagnosed as mild or moderate. Different clinical classification in age (P =.041), exposure history (P =.025), fever (P =.020), and cough (P =.000) were the statistically significant difference, but there was no statistically significant difference in gender (P =.501), the type of diagnosis (P =.478), expectoration (P =.979), fatigue (P =.906), dizziness or headache (P =.848), muscle pain (P =.825), sore throat or throat discomfort (P =.852), chills (P =.933), diarrhea (P =.431) and runny nose or nasal congestion (P =.898). This study shows that Beijing's epidemic scope was mainly concentrated in the Xinfadi Market. The initial cases were epidemiologically related to the BXM, the clinical classification of most cases was mild and moderate, and the differences in age, exposure history, fever, and cough among different clinical cases were statistically significant.